LVM Capital Management Ltd. MI Buys 8,576 Shares of Stryker Corporation $SYK

Key Points

• LVM Capital Management increased its Stryker stake by 15.9% in the second quarter, purchasing 8,576 shares for a total holding of 62,584 shares valued at approximately $19.7 million.
• Stryker reported quarterly earnings of $3.69 per share, beating estimates, while revenue rose 9.4% year over year to $6.59 billion. Analysts maintain a “Moderate Buy” consensus with an average price target of $386.28.
• The company declared a quarterly dividend of $0.88 per share, equivalent to an annualized $3.52 payout and a 1.0% yield. Meanwhile, insiders—including Director Ronda E. Stryker—recently sold substantial amounts of stock.

LVM Capital Management Ltd. MI raised its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 15.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,584 shares of the medical technology company's stock after purchasing an additional 8,576 shares during the period. Stryker accounts for approximately 1.6% of LVM Capital Management Ltd. MI's holdings, making the stock its 19th biggest position. LVM Capital Management Ltd. MI's holdings in Stryker were worth $19,704,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in SYK. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker in the 4th quarter worth $26,000. Sankala Group LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG bought a new position in shares of Stryker in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.60% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of SYK stock opened at $345.05 on Tuesday. The company has a market capitalization of $132.35 billion, a P/E ratio of 35.76, a P/E/G ratio of 2.16 and a beta of 0.76. The company's 50-day simple moving average is $321.03 and its two-hundred day simple moving average is $333.81. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker's payout ratio is 36.48%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Argus set a $370.00 price objective on Stryker in a research note on Thursday, July 9th. UBS Group initiated coverage on Stryker in a report on Tuesday, July 28th. They issued a "buy" rating and a $400.00 target price for the company. Sanford C. Bernstein set a $410.00 target price on Stryker in a research report on Friday, May 1st. Raymond James Financial set a $370.00 price target on Stryker in a report on Friday, July 31st. Finally, BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a "buy" rating for the company in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source